South Korean clinical-stage biotech ABL Bio (Kosdaq: 298380) on Sunday announced a worldwide licensing agreement enabling GSK ...

GSK's clinical-stage pipeline is currently focused on oncology, respiratory, immunology and inflammation, and infectious ...

The pharma giant is wagering potentially billions of dollars on technology from ABL Bio that’s designed to get drugs across ...

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...

Explore how U.S. tariffs and vaccine skepticism may impact GSK plc's profitability. Click for my update as tariffs are ...

Learn more about whether Corcept Therapeutics Incorporated or GSK plc is a better investment based on AAII's A+ Investor ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

GSK (LON:GSK – Get Free Report)‘s stock had its “underweight” rating reaffirmed by equities research analysts at JPMorgan ...

GSK plc (NYSE:GSK) has several significant commercial developments planned for 2025, with BLENREP’s relaunch being the ...

Stock analysts at Zacks Research upped their FY2027 earnings per share estimates for GSK in a report issued on Tuesday, March ...

The Food and Drug Administration (FDA) has approved a new drug for treating urinary tract infections, the first such drug ...

Blujepa is the first in a new class of oral antibiotics in 30 years. It is expected to launch in the second half of 2025 in the United States.